Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,258,701 papers from all fields of science
Search
Sign In
Create Free Account
GFT505
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Combination drug therapy allows synergistic therapeutic dose reduction in NASH: a case study of elafibranor (GFT505) and an FXR agonist combination in a model of severe NASH
V. Ratziu
,
S. Harrison
,
+10 authors
A. Sanyal
2017
Corpus ID: 80012728
2016
2016
Preparation and intermediates Gft505
应述欢
,
皮红军
,
陈健
,
邹宝勤
,
何淼
2016
Corpus ID: 104452560
The present invention discloses a method for preparing GFT505 and intermediates thereof. The present invention provides a method…
Expand
2014
2014
The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma–associated adverse…
Rémy Hanf
,
L. Millatt
,
+6 authors
B. Staels
Diabetes & vascular disease research
2014
Corpus ID: 206735893
We report here the efficacy and safety of GFT505, a novel liver-targeted peroxisome proliferator-activated receptor alpha/delta…
Expand
Review
2014
Review
2014
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes
B. Cariou
,
B. Staels
Expert Opinion on Investigational Drugs
2014
Corpus ID: 3190253
Introduction: PPARs are nuclear receptors that play key roles in the regulation of metabolism and inflammation. GFT505 is a new…
Expand
2013
2013
O45 Le GFT505, un co-agoniste PPARα/δ, améliore la sensibilité périphérique et hépatique à l’insuline chez des patients obèses insulinorésistants
B. Cariou
,
Rémy Hanf
,
+5 authors
M. Laville
2013
Corpus ID: 72649250
2013
2013
Nuclear control of inflammation and fibrosis in nonalcoholic steatohepatitis: therapeutic potential of dual peroxisome proliferator‐activated receptor alpha/delta agonism
P. Quintero
,
M. Arrese
Hepatology
2013
Corpus ID: 2177203
N onalcoholic fatty liver disease (NAFLD) is currently regarded as the most common liver disease worldwide, affecting 25%-30% of…
Expand
2012
2012
1410 A RANDOMIZED, CONTROLLED, MULTICENTRE TRIAL COMPARING ENDOSCOPIC BAND LIGATION VERSUS TIPS IN CIRRHOTIC PATIENTS WITH RECURRENT VARICEAL BLEEDING NON-RESPONDING TO PHARMACOLOGICAL THERAPY
A. Ferlitsch
,
G. Ulbrich
,
+5 authors
M. Peck‐Radosavljevic
2012
Corpus ID: 76630548
2012
2012
1409 THE NEW DUAL PPARα/δ AGONIST GFT505 IMPROVES HEPATIC INSULIN RESISTANCE AND DECREASES SERUM LIVER ENZYMES IN ABDOMINALLY OBESE PATIENTS
B. Cariou
,
Rémy Hanf
,
+4 authors
M. Laville
2012
Corpus ID: 70459278
Highly Cited
2011
Highly Cited
2011
Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
B. Cariou
,
Y. Zaïr
,
B. Staels
,
E. Bruckert
Diabetes Care
2011
Corpus ID: 11422059
OBJECTIVE We evaluated the metabolic effects and tolerability of GFT505, a novel dual peroxisome proliferator–activated receptor…
Expand
2011
2011
Effects of the NewDual PPAR a / d Agonist GFT 505 on Lipid and Glucose Homeostasis in Abdominally Obese PatientsWith Combined Dyslipidemia or Impaired GlucoseMetabolism
B. Cariou
,
Y. Zaïr
,
B. Staels
,
E. Bruckert
2011
Corpus ID: 30880645
RESEARCH DESIGN AND METHODSdThe S1 study was conducted in 94 patients with combined dyslipidemia while the S2 study was conducted…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required